Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

The Ohio Clinical Trial Collaborative (OCTC)

The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.

The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.

Review the OCTC working website at: http://ohioclintrials.org.

Contact Joe Peter at 216-702-5314 for more information.

 
New Video and Quiz Available for CREC

Engaging in Cultural Competence through Awareness, Knowledge and Action
3 CREC


Watch the video and take the quiz for credit!

https://research.case.edu/Education/CREC_Video.cfm.

 
New Policy from NIH to Balance Sex in Cell and Animal Studies

NIH announced last week a new policy requiring "a balance of male and female cells and animals in preclinical studies in all future applications." In this week's Nature, Janine Clayton and Francis Collins write, "The over-reliance on male animals and cells in preclinical research obscures key sex differences that could guide clinical studies. And it might be harmful: women experience higher rates of adverse drug reactions than men do. Furthermore, inadequate inclusion of female cells and animals in experiments and inadequate analysis of data by sex may well contribute to the troubling rise of irreproducibility in preclinical biomedical research."

Read more at: http://ow.ly/wSqy6.

 
Patient-Centered Outcomes Research Institute (PCORI)

Pipeline to Proposal Awards Tier I - Pre-Engagement/Community Projects fund the building of the community and capacity necessary to later develop a patient-centered comparative effectiveness research (CER) project addressing the issue of interest to the awardee

The Tier I awards are for individuals or groups who are not usual candidates for research funding. This program is intended to support those individuals and groups with critically important ideas who may not have other opportunities for research funding. In order to qualify for Tier I funding, you must demonstrate success in a past community-building project. The project doesn’t have to have been health-related. You need to explain how you engaged the community and formed partnerships to achieve your goal and how, by building relationships and forming partnerships, you were able to overcome any obstacles.

Letter of Intent (LOI) deadline: December 23, 2014

Application Deadline: February 16, 2015

Funds available up to: $15,000

For more information, visit the PCORI website.

 

Case Comprehensive Cancer Center

All Faculty members are invited to submit concept proposals for 5 year Projects to compete for incorporation as a full project proposal in the upcoming GI SPORE competing renewal application that will be prepared starting in January 2015 for submission in September 2015 All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or of human tissues.

Proposals must include two project leaders; one Basic Science leader and one Clinical leader. Maximum Funding Level – $185,000/year direct cost for 5 years ($925,000 total direct costs).

Completed proposals must be emailed to John Pounardjian, hxp125@case.edu. For more information on GI SPORE, visit the CaseCCC website.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.